The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study

References

• Ferlay J, Lam F, Colombet M, et al. Global cancer observatory: cancer today. Lyon: Fr Int Agency Res Cancer; Published online 2018 [cited 2020 May 11]. Available from: https//gco.iarc.fr/today.
   Google Scholar
• Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Interv Radiol. 2013;30(2):93–6.
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Damotte D, Hofman V, et al. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. J Thorac Dis. 2019;11(Suppl1):S89–S101.
   Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222.
   PubMed Web of Science ®Google Scholar
• Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019;7(5):437–446.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol. 2019;37(16):1370–1379.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012;118(18):4502–4511.
   PubMed Web of Science ®Google Scholar
• Kerr KM, Thunnissen E, Dafni U, et al. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European thoracic oncology platform (ETOP) lungscape project. Lung Cancer. 2019;131:95–103.
   Web of Science ®Google Scholar
• Sepesi B, Nelson DB, Mitchell KG, et al. Prognostic value of PD-L1 mRNA sequencing expression profile in non-small cell lung cancer. Ann Thorac Surg. 2018;105(6):1621–1626.
   Web of Science ®Google Scholar
• Brody R, Zhang Y, Ballas M, et al. PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200–215.
   PubMed Web of Science ®Google Scholar
• Terry L Ng; , Yiwei Liu, and Anastasios, Dimou et al. Predictive value of oncogenic driver subtyde, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy og PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer 125 (7) . 1038–1049 doi:https://doi.org/10.002/cncr.31871. Published online 2019. Published online 2019
   Web of Science ®Google Scholar
• Zhang P, Wu X, Tang M, et al. Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma. Thorac Cancer. 2019;10(12):2218–2224.
   Web of Science ®Google Scholar
• Morgensztern D, Waqar S, Subramanian J, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7(10):1485–1489.
   PubMed Web of Science ®Google Scholar
• Arnold DT, De Fonseka D, Perry S, et al. Investigating unilateral pleural effusions: the role of cytology. Eur Respir J. 2018;52:5.
   Google Scholar
• Pang C, Ma H, Qin J, et al. Pleural effusion as a substitute for tumour tissue in detecting EGFR/ALK mutations in non-small cell lung cancer: a systematic review and meta-analysis. Med (USA). 2019;98:18.
   Google Scholar
• Grosu HB, Arriola A, Stewart J, et al. PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC. Respirology. 2019;24(12):1198–1203.
   PubMed Web of Science ®Google Scholar
• Song Z, Cheng G, Zhang Y. PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. J Thorac Dis. 2020;12(4):1385–1392.
   Web of Science ®Google Scholar
• DeMaio A, Clarke JM, Dash R, et al. Yield of malignant pleural effusion for detection of oncogenic driver mutations in lung adenocarcinoma. J Bronchol Interv Pulmonol. 2019;26(2):96–101.
   Web of Science ®Google Scholar
• Heymann JJ, Bulman WA, Swinarski D, et al. PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol. 2017;125(12):896–907.
   Web of Science ®Google Scholar
• Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119(2):111–117.
   Web of Science ®Google Scholar
• Betz BL, Dixon CA, Weigelin HC, et al. The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. Cancer Cytopathol. 2013;121(9):489–499.
   PubMed Web of Science ®Google Scholar
• Rosenblum F, Hutchinson LM, Garver J, et al. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma. Cancer Cytopathol. 2014;122(11):810–821.
   PubMed Web of Science ®Google Scholar
• Carter J, Miller JA, Feller-Kopman D, et al. Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma. the effect of preanalytical factors. Ann Am Thorac Soc. 2017;14(7):1169–1176.
   Web of Science ®Google Scholar
• Wang H, Agulnik J, Kasymjanova G, et al. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Ann Oncol. 2018;29(6):1417–1422.
   Web of Science ®Google Scholar
• Wang X, Chen S, Emerson RE, et al. Molecular testing for EGFR mutations and ALK rearrangements in the cytological specimens from the patients with non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2019;27(2):119–124.
   Google Scholar
• Wang W, Tang Y, Li J, et al. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Cancer Cytopathol. 2015;123(2):117–122.
   Web of Science ®Google Scholar
• Hooper C, Lee YC, Maskell N; Group BTSPG. Investigation of a unilateral pleural effusion in adults: British thoracic society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii4–17.
   PubMed Web of Science ®Google Scholar
• Thunnissen E, Kerr KM, Herth FJF, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer. 2012;76(1):1–18.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Shen Q, Wang X, Yu B, et al. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC). Lung Cancer. 2015;90(3):492–498.
   PubMed Web of Science ®Google Scholar
• Koitzsch U, Heydt C, Attig H, et al. Use of the GeneReader NGS system in a clinical pathology laboratory: a comparative study. J Clin Pathol. 2017;70(8):725–728.
   Web of Science ®Google Scholar
• Liu L, Zhan P, Zhou X, et al. Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods. PLoS One. 2015;10(3):1–9.
   Web of Science ®Google Scholar
• Abouzgheib W, Bartter T, Dagher H, et al. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest. 2009;135(4):999–1001.
   Web of Science ®Google Scholar